Objective:To investigate the effects of laparoscopic surgery combined with triptorelin acetate, gestrinone and mifepristone on pregnancy rate, pregnancy outcome, long-term recurrence and adverse reactions in patients with endometriosis (EMT) complicated with infertility.Methods:In this study, 150 patients with EMT and infertility were selected and randomly divided into triptorelin group (group A), gestrinone group (group B) and mifepristone group (group C), with 50 people in each group. Treatment was with gonadotropin-releasing hormone (GnRH-a) after laparoscopic surgery.Results:The success rate of pregnancy in group A was higher than that in group B and C. The incidence of adverse pregnancy outcome was lower than that in group B and C. Kupperman score and subjective symptom score were lower than those in group B and C before treatment. Sex hormone level and CA125 level were significantly better. In the B and C groups and before treatment; the long-term recurrence rate was significantly lower than the B and C groups; the incidence of adverse reactions was similar.Conclusion:Laparoscopic surgery combined with GnRH-a can improve the success and good rate of pregnancy in EMT patients, reduce clinical symptoms, avoid long-term recurrence, and increase the risk of adverse reactions. Triptorelin acetate is superior to gestrinone and mifepristone.

Objective:To evaluate the clinical therapeutic effects of mifepristone combined with gestrinone on patients with endometriosis.Methods:A total of 150 endometriotic patients treated in our hospital between January 2014 and December 2015 were randomly divided into a control group and a treatment group (n=75). The control group began to orally take gestrinone capsules on the second day after menstruation started (2.5 mg/time, twice/week). The treatment group orally took mifepristone tablets (12.5 mg/time, once/day), and the dosage and administration of gestrinone capsules were the same as those of the control group. After 24 weeks of consecutive treatment, the clinical therapeutic effects of the two groups were assessed, and the pelvic symptom score, clinical sign score, serum sex hormone levels and pregnancy outcomes were compared.Results:The total effective rates of control and treatment groups were 77.3% and 90.7% respectively, between which the difference was statistically significant (P<0.05). After treatment, the scores of pelvic symptoms (dysmenorrhea, dyspareunia, pelvic pain) and clinical signs (pelvic tenderness, induration) significantly reduced (P<0.05). Each score of the treatment group decreased more significantly than that of the control group did (P<0.05). The serum follicle hormone, luteinizing hormone, estrogen and progesterone levels were significantly lower than those before treatment (P<0.05). Each level of the treatment group dropped more significantly than that of the control group did (P<0.05). The pregnancy rates in the 6th and 12th months of follow-up were 28.0% and 13.3% in the control group respectively, and 42.7% and 29.3% in the treatment group respectively. Such rates of the two groups were significantly different at each follow-up time point (P<0.05).Conclusion:Mifepristone combined with gestrinone had satisfactory clinical therapeutic effects on endometriosis by reducing hormone levels and improving pregnancy outcomes. Therefore, this regimen is worthy of promotion and application in clinical practice.

No abstract

The underlying mechanisms of intracranial aneurysm (IA) formation and rupture are still unclear. Evidence has proved that it might be closely related to inflammatory response and oxidative stress. Our objective was to identify novel inflammatory and oxidative stress related biomarkers to assist IA management. In this study, the enzyme-linked immunosorbent assay was performed to measure the expression levels of CD36 and glutathione (GSH) in the plasma of 30 IA patients and 30 healthy controls. Then, correlation analysis and receiver operating characteristic (ROC) curve, and logistic regression analysis were applied to investigate CD36 and GSH as potential biomarker for IA. The expression level of plasma CD36 in the IA patients was significantly higher than that in the control group (P < 0.0001), and the level of plasma GSH in the IA patients was significantly lower than that in the control group (P < 0.0001). The plasma level of CD36 and GSH did not show significant correlation with age, Glasgow Coma Scale (GCS), Hunter-Hess score, aneurysm size, aneurysm height, aneurysm neck, and aspect ratio. ROC analysis showed that CD36 and GSH had high sensitivity (90.0%, 96.6%) and specificity (96.6%, 86.6%) for IA diagnosis. And the combined sensitivity and specificity achieved 100% and 100%, respectively. The AUC of logistic regression model based on CD36 and GSH was 0.505. Our results suggested that CD36 and GSH might participate in the process of IA formation and rupture but did not affect its morphology. Moreover, the combination plasma CD36 and GSH could serve as potential biomarker for IA rupture.